Matt Kapusta, uniQure CEO (via website)

UniQure gets an­oth­er shot with he­mo­phil­ia gene ther­a­py af­ter FDA lifts clin­i­cal hold; Ne­oleuk­in's IL-2 hope­ful al­so cleared

Months af­ter a dis­as­trous clin­i­cal hold on its he­mo­phil­ia B gene ther­a­py shut down de­vel­op­ment, uniQure had rea­son to be­lieve its drug wasn’t to blame …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.